Hamilton Thorne Ltd.

Hamilton Thorne reported Q1 2024 sales of $19.4 million, up 16% year over year and up 15% on a constant-currency basis; organic sales growth was approximately 9%. Gross profit was $9.2 million, up 20%, and gross margin was 52.4% versus 50.6% in the prior-year period. Adjusted EBITDA was $3.5 million, up 24% from $2.8 million, with EBITDA margin at 18% of sales; net loss was $936,000 versus net income of $77,000 in Q1 2023. Cash at March 31, 2024 was $7.5 million, down from $9.7 million at year-end 2023; note payables and term loans totaled $21 million. For full-year 2024, management reaffirmed revenue guidance of $78 million to $82 million and adjusted EBITDA margin of 19.5% to 20.5%, excluding future acquisitions.

Kate Torchilin said the company is focused on strengthening execution, improving operating efficiency, and driving profitable growth as she updates the five-year strategic plan. She emphasized Hamilton Thorne’s role as a premier innovator serving IVF/ART labs and said the company will continue to fine-tune its product, regional, and investment priorities. Her tone was constructive and confident, with repeated comments that demand remains solid and that the company is “quite bullish” on the year.

Francesco Fragasso highlighted operating expenses of $9.5 million, up $2 million or 27%, with about $0.8 million of the increase tied to D&A from acquired assets and capacity investments and $0.9 million tied to growth-related hiring and commercial investment. Net interest expense increased to $525,000, net loss was $936,000, and adjusted EBITDA increased to $3.5 million. He said cash from operations was $648,000 versus $525,000 used in operations a year ago, investing cash usage was $1.9 million, and financing cash usage was $767,000; liquidity was described as $12 million including $7.5 million cash and $4.5 million unused borrowing capacity. He also said CapEx and capitalized product development are front-loaded, with the full-year plan still at $2.6 million for PP&E and product development capitalization.

Analysts focused on the M&A-driven channel shift, cross-selling opportunity, and how much margin upside remains from internalizing distribution, and management said the process is ongoing but “not done.” They also asked about capacity expansion, and Francesco said the company was not constrained in the past but would have been this year without the expansion; he expects better efficiency and eventually lower manufacturing/logistics costs. Questions on Q1 margin timing and guidance led management to say Q1 is the low point for the year, the second half should be stronger, and no major new Q2 headwinds are currently visible. Analysts also probed China and APAC growth, with management saying China is stable while APAC ex-China is growing strongly, especially in Japan, Australia, Vietnam, and Thailand.